Unlock MRD everywhere

Transform any sequencer or dPCR into a single-ppm cancer-radar—tissue-free, immediate, and accessible.

Request Early Access

Why We Exist

Cancer relapse is as much a logistics challenge as a biological one. Centralized testing, tissue limitations, and lengthy turnaround times prevent timely access to critical Minimal Residual Disease (MRD) insights.

Tracer revolutionizes MRD testing by decentralizing the workflow, delivering answers where patient care happens.

Proud partners of

Our Platform

Enabling the future of MRD detection

Plug-&-Play

Seamlessly integrate our software into any high-throughput NGS instrument e.g. NovaSeq, Ultima, or MGI or commercial dPCR system. Convert raw data into quantitative Tumor Fraction reports.

Flexible Deployment

Stream FASTQs to our secure cloud for results in under 48 hours, or deploy our encrypted on-premise solution for same-day insights within your network.

Vendor-Agnostic Advantage

Leverage your existing generic WGS or dPCR reagents. Eliminate vendor lock-in and reduce costs.

The Power of Decentralization

Empowering every hospital, CRO, and biopharma site to become an immediate MRD service provider.

Book a demo

Our OFFERINGS

WGS MRD

dPCR MRD

Core Tech

Comprehensive plasma whole-genome sequencing (30x-300x) with advanced AI-powered signal extraction

High-sensitivity patient-specific dPCR panels

Sensitivity

10 ppm tumor-naïve
1 ppm tumor-informed

10-100 ppm

Turnaround

< 48 h in-house
< 7 days via partner labs

< 24 h in-house

Ideal Use

Neoadjuvant settings with no tissue, early-line chemo de-escalation

High-frequency monitoring, exploratory pharma cohorts, studies with tissue biomarker data but no available tissue

Cost

$1,000–$3,000 per time-point

$5,000 unlimited time-points per patient

Transforming Cancer Care

Ultrasensitive, Scalable, Decentralized MRD

Neoadjuvant & Tissue-Limited Settings:  Enable early detection of molecular response before surgery, even in the absence of tumor tissue.
Long-Term Surveillance:  Cost-effective dPCR panels facilitate frequent, longitudinal monitoring without significant financial burden.
Chemo De-escalation & Adaptive Therapy:  Single-part-per-million (ppm) sensitivity empowers clinicians to make informed decisions on therapy intensity adjustments.
Global Pharma Research:  Conduct MRD analysis across global sites instantly, overcoming sample export and regulatory hurdles.

Request Early Access

The Tracer Workflow

Seamless Integration, Powerful Insights

Tissue-free, Plug-and-play

1 Draw & Spin

Collect 10 mL plasma; standard cfDNA prep.

2 Choose Your Lane

Local / Decentralized: Run 30×–300× generic WGS on your own NovaSeq™ or Ultima™.
Central Lab: Overnight the plasma to any of our CLIA-certified partner labs and we sequence for you.

3 Secure Upload / Local Sync

FASTQs flow to our cloud or on-prem Tracer Server.

4 AI Signal Extraction

Millions of loci modeled to single-ppm Tumor Fraction.

5 Actionable Report

PDF and structured data returned in < 48 h (local) or < 7 days (central lab).

Tumor-informed, Primer-ready

1 Nominate Targets

Send us a tumor VCF or hotspot list; we design a multiplex primer-probe set in < 5 days.

2 Choose Your Lane

Local / Decentralized: We drop-ship the custom reagents; you run droplets on any major dPCR platform.
Central Lab (CLIA) or Tracer RUO Core: Ship plasma to our CLIA partner network for clinical testing or to the Tracer RUO central lab for exploratory pharma studies.

3 Secure Upload / Local Sync

Raw droplet counts stream to Tracer; software auto-QC’s and quantifies ctDNA.

4 Ultra-Low Cost Surveillance

Quantitative MRD trendlines delivered in < 24 h (local) or < 4 days (central).

5 Unified Dashboard & API

Both routes feed into the same Tracer portal for seamless study management.

One platform, two modalities

Run in-house, use our CLIA network, or tap the Tracer RUO core. MRD wherever you need it.

Book a demo

The Tracer Advantage

Accelerated Trials

Decentralized MRD testing at the site level enables adaptive study designs and significantly reduces turnaround times associated with sample transport.

Cost-Effective Solution

Leveraging generic reagents and existing infrastructure maximizes budget allocation towards patient care, not proprietary costs.

Global Accessibility

Our open ecosystem ensures seamless MRD testing in any lab, across any geography, facilitating global precision oncology initiatives.

Future-Proof Technology

Our software-centric approach with continuous machine learning updates enhances sensitivity without the need for changes in laboratory protocols.

Get Started

Ready to turn your sequencers into MRD engines? Schedule a live demo or download the integration brief to see how quickly you can be up and running.

Your form has been submitted

Someone on our team will reach out to you shortly.

Oops! Something went wrong while submitting the form.